XENETIC BIOSCIENCES, INC. Derivative Liability, Fair Value, Gross Liability
XENETIC BIOSCIENCES, INC. (XBIO) had Derivative Liability, Fair Value, Gross Liability of $2.80 million as of 2015-09-30, per its 10-Q filed 2015-11-16.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2015-11-16
- 2015-09-30: Derivative Liability, Fair Value, Gross Liability $2.80M.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2015-09-30 | $2.80M 10-Q · filed 2015-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |